Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1983 Apr;67(4):216–219. doi: 10.1136/bjo.67.4.216

Blind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma.

K B Mills
PMCID: PMC1040022  PMID: 6338905

Abstract

The results of a 12-month blind randomised trial comparing the intraocular pressure lowering effect of timolol 0.25% with timolol 0.5% are presented. 27% of patients (22% of eyes) required additional antiglaucoma medication after a minimum time interval of 6 months to maintain an intraocular pressure less than 23 mmHg. The mean reduction in intraocular pressure (from pretreatment values) at 12 months was 24% for eyes treated with timolol 0.25% and 19% for eyes treated with timolol 0.5%. When reductions in intraocular pressure at each follow-up interval were statistically significant (timolol 0.25% treated eyes compared with timolol 0.5% treated eyes), the significance always favoured timolol 0.25%.

Full text

PDF
216

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boger W. P., 3rd, Puliafito C. A., Steinert R. F., Langston D. P. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology. 1978 Mar;85(3):259–267. doi: 10.1016/s0161-6420(78)35673-6. [DOI] [PubMed] [Google Scholar]
  2. Boger W. P., 3rd Timolol: short term "escape" and long term "drift". Ann Ophthalmol. 1979 Aug;11(8):1239–1242. [PubMed] [Google Scholar]
  3. Boger W. P., 3rd Timolol: short term "escape" and long term "drift". Ann Ophthalmol. 1979 Aug;11(8):1239–1242. [PubMed] [Google Scholar]
  4. Coakes R. L., Brubaker R. F. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol. 1978 Nov;96(11):2045–2048. doi: 10.1001/archopht.1978.03910060433007. [DOI] [PubMed] [Google Scholar]
  5. Hall R. A., Robson R. D., Share N. N. Timolol maleate, a new beta-adrenergic receptor blocking agent. Arch Int Pharmacodyn Ther. 1975 Feb;213(2):251–263. [PubMed] [Google Scholar]
  6. Katz I. M., Hubbard W. A., Getson A. J., Gould A. L. Intraocular pressure decrease in normal volunteers following timolol ophthalmic solution. Invest Ophthalmol. 1976 Jun;15(6):489–492. [PubMed] [Google Scholar]
  7. Neufeld A. H., Zawistowski K. A., Page E. D., Bromberg B. B. Influences on the density of beta-adrenergic receptors in the cornea and iris--ciliary body of the rabbit. Invest Ophthalmol Vis Sci. 1978 Nov;17(11):1069–1075. [PubMed] [Google Scholar]
  8. Nielsen N. V. Timolol. Hypotensive effect, used alone and in combination for treatment of increased intraocular pressure. Acta Ophthalmol (Copenh) 1978;56(4):504–509. [PubMed] [Google Scholar]
  9. Wilson R. P., Spaeth G. L., Poryzees E. The place of timolol in the practice of ophthalmology. Ophthalmology. 1980 May;87(5):451–454. doi: 10.1016/s0161-6420(80)35214-7. [DOI] [PubMed] [Google Scholar]
  10. Zimmerman T. J., Kass M. A., Yablonski M. E., Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol. 1979 Apr;97(4):656–658. doi: 10.1001/archopht.1979.01020010312004. [DOI] [PubMed] [Google Scholar]
  11. Zimmerman T. J., Kaufman H. E. Timolol, dose response and duration of action. Arch Ophthalmol. 1977 Apr;95(4):605–607. doi: 10.1001/archopht.1977.04450040071009. [DOI] [PubMed] [Google Scholar]
  12. Zimmerman T. J., Kaufman H. E. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977 Apr;95(4):601–604. doi: 10.1001/archopht.1977.04450040067008. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES